Evidence map›Paper›PMID 31937932›Full record

ArticleActa pharmacologica Sinica2020

IgD-Fc-Ig fusion protein, a new biological agent, inhibits T cell function in CIA rats by inhibiting IgD-IgDR-Lck-NF-κB signaling pathways.

Le Han, Xian-Zheng Zhang, Chen Wang, Xiao-Yu Tang, Yue Zhu, Xiao-Yu Cai, Yu-Jing Wu, Jin-Ling Shu, Qing-Tong Wang, Jing-Yu Chen and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Acta pharmacologica Sinica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Kirenol relieves rheumatoid arthritis by targeting the TWEAK/Fn14 pathway.International journal of molecular medicine · 2025
    Article
  3. Article
  4. Therapeutic Fusion Proteins.The AAPS journal · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Le Han *Institute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.
Xian-Zheng Zhang *Institute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.
Chen WangInstitute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.
Xiao-Yu TangInstitute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.
Yue ZhuInstitute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.
Xiao-Yu CaiInstitute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.
Yu-Jing WuInstitute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.
Jin-Ling ShuInstitute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.
Qing-Tong WangInstitute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.
Jing-Yu ChenInstitute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.
Yan ChangInstitute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.
Hua-Xun WuInstitute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.
Ling-Ling ZhangInstitute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China. ll-zhang@hotmail.com.
Wei WeiInstitute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China. wwei@ahmu.edu.cn.
Anhui Mental Health Center · CNMinistry of Education of the People's Republic of China · CNAnhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IgD-Fc-Ig fusion protein, a new biological agent, is constructed by linking a segment of human IgD-Fc with a segment of human IgG1-Fc, which specifically blocks the IgD-IgDR pathway and selectively inhibits the abnormal proliferation, activation, and differentiation of T cells. In this study we investigated whether IgD-Fc-Ig exerted therapeutic effects in collagen-induced arthritis (CIA) rats. CIA rats were treated with IgD-Fc-Ig (1, 3, and 9 mg/kg) or injected with biological agents etanercept (3 mg/kg) once every 3 days for 40 days. In the PBMCs and spleen lymphocytes of CIA rats, both T and B cells exhibited abnormal proliferation; the percentages of CD3

Indexed as

Signal TransductionAcetic AcidAnimalsArthritis, ExperimentalImmunoglobulin DImmunoglobulin Fc FragmentsMaleNF-kappa BRatsRats, WistarReceptors, IgGT-LymphocytesAcetic AcidImmunoglobulin DImmunoglobulin Fc FragmentsNF-kappa BReceptors, IgGCD4+ T cellcollagen-induced-arthritisetanerceptIgDIgD-Fc-Ig fusion proteinIgD-IgDR-Lck-NF-κB signalingIgDR

Identifiers

PMID31937932
PMCPMC7470893
OpenAlexW2999817830

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.